|
|
|
March 03, 2005
Aspreva Pharmaceuticals Announces Pricing
of Initial Pricing of Initial Public Offering at US$11.00
(C$13.68) Per Share
Aspreva Pharmaceuticals pioneered a novel specialty
pharmaceuticals model, indication partnering: expanding
the marketing label of already-approved products and selling
the product in the new markets. Its first product was
CellCept mycophenolate mofetil for autoimmune disorders.
Within a year of our investment, the company’s first
institutional financing, Aspreva went public [NASDAQ:
ASPV].
--------------------------------
Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX:
ASV), today announced the closing of its initial public
offering of 8,280,000 common shares at US$11.00 (C$13.68)
per share. The shares are listed on the Nasdaq National
Market under the trading symbol ASPV and the Toronto Stock
Exchange under the trading symbol ASV.
The offering was made through an underwriting syndicate
led by Merrill Lynch & Co., co-led by Banc of America
Securities LLC, and co-managed by Pacific Growth Equities
LLC and BMO Nesbitt Burns Inc.
Back to News
|
|
| |
